{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:40:03Z","timestamp":1794264003085,"version":"4.9.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.healun.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:36:36Z","timestamp":1763969796000},"page":"442-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent\/recurrent chronic thromboembolic pulmonary hypertension"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-7580","authenticated-orcid":false,"given":"David P.","family":"Jenkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofija","family":"Cerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7797-2615","authenticated-orcid":false,"given":"D\u00e9nes","family":"Csonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein-Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-9574","authenticated-orcid":false,"given":"Stefan","family":"Guth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-2599","authenticated-orcid":false,"given":"Gustavo A.","family":"Heresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noormaa","family":"Jaumdally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Cheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Lack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-650X","authenticated-orcid":false,"given":"Nick H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.healun.2025.11.014_bib1","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1513\/AnnalsATS.201509-620AS","article-title":"The pathobiology of chronic thromboembolic pulmonary hypertension","volume":"13","author":"Lang","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"143","key":"10.1016\/j.healun.2025.11.014_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2016","article-title":"The pathophysiology of chronic thromboembolic pulmonary hypertension","volume":"26","author":"Simonneau","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.healun.2025.11.014_bib3","doi-asserted-by":"crossref","first-page":"2002828","DOI":"10.1183\/13993003.02828-2020","article-title":"ERS statement on chronic thromboembolic pulmonary hypertension","volume":"57","author":"Delcroix","year":"2021","journal-title":"Eur Respir J"},{"issue":"38","key":"10.1016\/j.healun.2025.11.014_bib4","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.healun.2025.11.014_bib5","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.healun.2025.11.014_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01294-2024","article-title":"Chronic thromboembolic pulmonary disease","volume":"64","author":"Kim","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2025.11.014_bib7","unstructured":"Opsumit\u00ae (macitentan). Full Prescribing Information. Actelion Pharmaceuticals US, Inc. March 2025."},{"key":"10.1016\/j.healun.2025.11.014_bib8","unstructured":"Opsumit\u00ae (macitentan). Summary of product characteristics. Actelion Pharmaceuticals Ltd, Inc. November 2024."},{"issue":"9","key":"10.1016\/j.healun.2025.11.014_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.healun.2025.11.014_bib10","doi-asserted-by":"crossref","first-page":"2000673","DOI":"10.1183\/13993003.00673-2020","article-title":"Initial combination therapy with macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension: Results from the OPTIMA trial","volume":"56","author":"Sitbon","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2025.11.014_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3319","article-title":"Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities","author":"McLaughlin","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.healun.2025.11.014_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jcmg.2021.07.027","article-title":"The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension","volume":"15","author":"Vonk Noordegraaf","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.healun.2025.11.014_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12150","article-title":"Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit\u00ae USers Registry (OPUS) and OPsumit\u00ae Historical USers cohort (OrPHeUS)","volume":"12","author":"McLaughlin","year":"2022","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.healun.2025.11.014_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79623-5","article-title":"Exploring the Endothelin-1 pathway in chronic thromboembolic pulmonary hypertension microvasculopathy","volume":"14","author":"Feriel","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.healun.2025.11.014_bib15","first-page":"e21","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. The Lancet. Respiratory medicine","volume":"12","author":"Ghofrani","year":"2024"},{"issue":"1","key":"10.1016\/j.healun.2025.11.014_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s41030-024-00276-w","article-title":"Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label Extension","volume":"11","author":"Kim","year":"2025","journal-title":"Pulm Ther"},{"issue":"1521-0103 (Electronic","key":"10.1016\/j.healun.2025.11.014_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharm Exp Ther"},{"issue":"1","key":"10.1016\/j.healun.2025.11.014_bib18","article-title":"Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma","volume":"3","author":"Weathers","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"2","key":"10.1016\/j.healun.2025.11.014_bib19","article-title":"UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH)","volume":"43","author":"McLaughlin","year":"2022","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.healun.2025.11.014_bib20","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Jais","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.healun.2025.11.014_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.healun.2025.11.014_bib22","doi-asserted-by":"crossref","first-page":"2400193","DOI":"10.1183\/13993003.00193-2024","article-title":"Efficacy and safety of selexipag in patients with inoperable or persistent\/recurrent CTEPH (SELECT randomised trial)","volume":"64","author":"Kim","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.healun.2025.11.014_bib23","unstructured":"Johnson & Johnson Innovative Medicine. Clinical trial data transparency. Accessed March 2025. \u3008https:\/\/innovativemedicine.jnj.com\/our-innovation\/clinical-trials\/transparency\u3009."},{"key":"10.1016\/j.healun.2025.11.014_bib24","unstructured":"Yale University. The Yoda project. Accessed March 2025. \u3008http:\/\/yoda.yale.edu\u3009."}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825024027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825024027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:38:34Z","timestamp":1773941914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249825024027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1053249825024027"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2025.11.014","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent\/recurrent chronic thromboembolic pulmonary hypertension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}]}}